← Back
Data updated: Mar 10, 2026
BAUSCH AND LOMB
OphthalmologyCardiovascularInfectious Disease
BAUSCH AND LOMB is a specialty pharmaceutical company focused on Ophthalmology, Cardiovascular, Infectious Disease. Key products include PROLENSA.
1978
Since
77
Drugs
-
Trials
184
Approved (2yr)
Key Drugs
XIPERE
triamcinolone acetonide
Glucocorticoid Receptor 2 indications · 2021
PROLENSA
bromfenac sodium
COX-1 2 indications · 2013
VYZULTA
latanoprostene bunod
2 indications · 2017
LOTEMAX SM
loteprednol etabonate
Glucocorticoid receptor 2 indications · 2019
XIIDRA
lifitegrast
LFA-1 1 indications · 2016
Recent Activity
BRIMONIDINE TARTRATE 2026-02-11
Labeling
METHAZOLAMIDE 2026-02-09
ATROPINE SULFATE 2026-02-04
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
ZIRGAN 2026-01-20
Labeling
OLOPATADINE HYDROCHLORIDE 2026-01-06
DICLOFENAC SODIUM 2025-12-31
Labeling
LATANOPROST 2025-12-17
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 47%
16 drugs
Cardiovascular 24%
8 drugs
Infectious Disease 15%
5 drugs
Dermatology 9%
3 drugs
Immunology 6%
2 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology, Ophthalmology
B BRAUN specialty
Infectious Disease, Ophthalmology, Dermatology, Cardiovascular
BAUSCH specialty
Dermatology, Immunology, Ophthalmology, Cardiovascular
Pfizer big-pharma
Infectious Disease, Dermatology, Immunology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Immunology
Active (41)
LUMIFY PRESERVATIVE FREE MIEBO XIPERE BRINZOLAMIDE LOTEMAX SM LUMIFY VYZULTA XIIDRA PROLENSA ZIRGAN BEPREVE BESIVANCE DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE DORZOLAMIDE HYDROCHLORIDE CHILDREN'S ALAWAY RETISERT ZYLET ISTALOL BRIMONIDINE TARTRATE PODOFILOX OFLOXACIN ALREX LOTEMAX TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE OTICAIR NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE DICLOFENAC SODIUM FLURBIPROFEN SODIUM OPCON-A CROMOLYN SODIUM TOBRAMYCIN TIMOPTIC-XE MIOCHOL-E METHAZOLAMIDE TIMOLOL MALEATE TIMOPTIC IN OCUDOSE HYDROCORTISONE AND ACETIC ACID TIMOPTIC PROPARACAINE HYDROCHLORIDE ERYTHROMYCIN SULFACETAMIDE SODIUM
Discontinued (34)
ATROPINE SULFATE NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE FLUOCINOLONE ACETONIDE PREDNISOLONE SODIUM PHOSPHATE DEXAMETHASONE SODIUM PHOSPHATE MINOXIDIL (FOR MEN) VITRASE GENTAMICIN SULFATE DEXASPORIN TOBRAMYCIN AND DEXAMETHASONE LEVOBUNOLOL HYDROCHLORIDE NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC ALAWAY PENTOLAIR NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE TROPICAMIDE BACITRACIN ZINC AND POLYMYXIN B SULFATE MACUGEN BROMDAY XIBROM LACRISERT OPTIPRANOLOL NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE CARTEOLOL HYDROCHLORIDE CROLOM DIPIVEFRIN HYDROCHLORIDE ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE NAFAZAIR VITRASERT NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE OPCON SULTEN-10 SULPHRIN
Company Info
- First Approval
- 1978-08-17
- Latest
- 2026-01-20
- Applications
- 84
FDA Sponsor Names
BAUSCH AND LOMBBAUSCH AND LOMB INC